"Not So Different": How the BPCIA Transition Will Impact Biosimilar Uptake

Apr 09, 2020, 08:48 PM

On March 23rd, 2020, the transition under the Biologics Price Competition and Innovation Act was complete, allowing products formerly classified as “small-molecule” drugs, including all insulin products, to be approved under the biologics regulatory pathway. This week on the podcast, we’re speaking with executive director of the Biologics and biosimilars collective intelligence consortium (also known as the BBCIC) , Cate Lockhart, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how this new transition will impact the market and uptake efforts.